Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was $15 million for the first quarter ...

In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company's financial direction continues to align with BioNTech's strategy to become a multi-product company in the oncology field. In ...

Mainz, Germany, May 5, 2025(Nasdaq: BNTX, "BioNTech" or "the Company") announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (" ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Welcome to the Adaptive Biotechnologies first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of ...

Between the early 1950s and mid-1960s, Roche’s pharmaceutical portfolio was extremely diverse ... Roche agreed to fully acquire biotech pioneer, Genentech, in which it had held a majority ...

KNIME, the company, has over 400 customers, including Audi, AMD, Lilly, Novartis, Bayer, Sanofi, Genentech, the FDA, P&G and Mercedes-Benz and nearly half a million open source users. KNIME ...

Prior to Gilead, from 2015 to 2019, Dr. Parsey served as senior vice president of early clinical development at Genentech, Inc. From 2010 to 2015, Dr. Parsey served as the chief executive officer ...

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...